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Background: Therapeutic gene delivery to the central nervous system (CNS) 
remains a challenge in Huntington’s disease research. The blood brain barrier 
restricts the delivery of therapeutic agents to various cell types in the CNS 
known to be involved in disease progression. Recombinant adeno-associated 
viral vectors (rAAVs) are frequently used for in vivo gene delivery in 
neurodegenerative research but can have poor or limited tropism in the CNS 
when delivered systemically. When injected directly into the CNS, AAVs are 
efficient at transducing a variety of cell types though with limited spread. 
Conversely, when naturally occurring AAVs are injected systematically they lead 
to widespread transgene expression but with low transduction efficiency.     
 
Aims: The aim of this experiment was to utilise a novel AAV variant, ssAAV-
PHP.B:CAG-GFP, to investigate and compare its transduction efficiency in brains 
of wild type (WT) and R6/2  mice.   
 
Methods: Four week old WT and R6/2 mice were intravenously injected through 
the tail vein with 5 × 109 vg/g with ssAAV-CAG-NLS-GFP packaged into AAV-
PHP.B. Three weeks later, the mice were perfused and the brains processed for 
immunohistochemistry. GFP expression was assessed using images captured by 
a laser scanning confocal microscope.  
 
Results: We show that systemic delivery of this AAV variant results in 
widespread and efficient GFP expression in different cell types throughout the 
CNS in both WT and R6/2 mice. Currently, we are assessing the impact of age 
and disease stage upon transduction efficiency.   
 
Conclusion: Our results demonstrate the potential for use of this AAV vector as an 
approach to knock-down or deliver genes of interest to the CNS. 
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